Novavax Inc.’s (NVAX) shares have experienced a precipitous decrease, plunging 17.03% in just five trading sessions while the NASDAQ index increased 1.12%. This steep fall has driven Novavax stock value well below both its 50-day moving average of $____.78 and 200-day moving average of $____.09. Additionally, recent closing prices were 88.11% below 52-week high of $____.24. The following will delve into some of the reasons for this decrease, including a deeper look at the company’s financial health and competition level.
About Novavax
Novavax, located in Maryland, is an innovative biotech company pioneering innovative vaccine development for serious infectious diseases using proprietary technology, nanoparticles and Matrix-M adjuvant. To date, Novavax has vaccines in development for COVID-19, influenza (both strains combined), respiratory syncytial virus infection and malaria; with more in various stages of production.
Novavax’s Financial Standing
As part of assessing Novavax’s financial health, one must look at their trailing 12-month EPS (Earnings Per Share) figure of 14.89. While this number provides insight into their profitability but doesn’t paint an accurate picture. Novavax has seen their quarterly year-on-year revenue growth drop 88.5% resulting in their trailing 12-month revenue being 1.36 billion with sales growth for current quarter sitting at 11.5% with projected -51.8% sales growth projection for next quarter.
Market Perception and Future Outlook
Novavax’s stock price plunge is evidence that investor trust has been breached. When taken together with its negative sales growth forecast and falling share price, it appears as though something may be amiss with Novavax’s product development or market competition – however given the nature of biotech industries and global health conditions there may be many variables at work which explain these trends – therefore an analysis of market conditions, competitors and the progress of Novavax vaccine trials must remain an essential step to informed investing.
More news about Novavax (NVAX).
